¡Todavía estás a tiempo de registrarte para unirte a nosotros! Te invitamos a participar con tu familia y amigos en una rodada especial para conmemorar el Día Mundial de la Trombosis.Será una jornada de convivencia, salud y conciencia sobre la prevención de esta enfermedad. Fecha: Domingo 19 de octubre de 2025Lugar: Parque Ecológico de XochimilcoAnillo…
Your opinion matters: Which treatment outcomes do you think are most important to measure in every blood clot (VTE) treatment study? The International VTE-COS Research Team invites people with lived or professional experience with VTE to participate in an online survey. Participation is voluntary and the survey should take 10-20 minutes to finish. The purpose…
Descarga: Remdesivir for the Treatment of Covid-19 — Preliminary Report Archivo: covid-19/Remdesivir for the Treatment of Covid-19 05 22 2020.pdf 2. Beigel J, Tomashek K, Dodd L, Mehta A, Zingman B, Kalil A et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report. New England Journal of Medicine. 2020;. BACKGROUNDAlthough several therapeutic agents have…
Descarga: A Systematic Approach for Managing Venous Thromboembolism in Patients with COVID-19: A Multinational Consensus Statement from the International Society on Thrombosis and Haemostasis (ISTH) on Behalf of the International Thrombosis Community Archivo: covid-19/CM_COVID 19 VTE Consensus Statement Final 9.11.20.pdf Documento PDF detectado.
Descarga: Thrombosis: a major contributor to the global disease burden Archivo: ISTH Steering Committee for World Thrombosis Day- Thrombosis a major contributor to the global disease burden 1.pdf ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost 2014; 12: 1580–90. Summary. Thrombosis is a common…
Descarga: The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients Archivo: covid-19/The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients. BLOOD.pdf The BTK-inhibitor ibrutinib is used to treat indolent B-cell malignancies and chronic graft versus host disease. The potential for ibrutinib to abrogate pulmonary inflammatory cytokines, lung injury and…
Descargar PDF — COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Preventio… Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition,…
Descarga: The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro Archivo: covid-19/The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.pdf Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously…
Descarga: Thrombosis management in times of COVID-19 epidemy; a Dutch perspective Archivo: covid-19/Hugo ten Cate- Thrombosis management in times of COVID-19 epidemy_ a Dutch perspective Thrombosis Journal.pdf 1. ten Cate H. Thrombosis management in times of COVID-19 epidemy; a Dutch perspective. Thrombosis Journal. 2020;18(1). The current pandemic of COVID-19 infection [1] has caused major shifts…
Descarga: Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 Archivo: covid-19/International Journal of Antimicrobial Agents- Journal PRE- Proof Chloroquine-and-hydroxychloroquine-f.pdf Repositioning of drugs for use as antiviral treatments is a critical need [1]. It is commonly very badly perceived by virologists, as we experienced when reporting the effectiveness of azithromycin for Zika virus [2]. A…
Por favor inicie sesión